257 related articles for article (PubMed ID: 35702829)
1. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
[TBL] [Abstract][Full Text] [Related]
2. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.
Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME
Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
4. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
Rajagopalan K; Rashid N; Kumar S; Doshi D
J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507
[TBL] [Abstract][Full Text] [Related]
5. Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis.
Rajagopalan K; Rashid N; Doshi D
J Comp Eff Res; 2024 Jan; 13(1):e230114. PubMed ID: 38099518
[No Abstract] [Full Text] [Related]
6. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
7. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
9. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
10. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
12. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
[TBL] [Abstract][Full Text] [Related]
13. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
[No Abstract] [Full Text] [Related]
14. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
15. Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
[TBL] [Abstract][Full Text] [Related]
16. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Sellers J; Darby RR; Farooque A; Claassen DO
Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
[TBL] [Abstract][Full Text] [Related]
17. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
[TBL] [Abstract][Full Text] [Related]
18. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Sahli ZT; Tarazi FI
Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
[TBL] [Abstract][Full Text] [Related]
19. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
[TBL] [Abstract][Full Text] [Related]
20. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
